Collaboration with Leading Kidney Care Vendors, Intelligent Health and Connected Care Showcased Culver City, CA and Orlando, FL — February...
NantHealth has validated successful DeviceConX™ integration with Baxter’s Prismaflex system, used to treat critically-ill patients in the ICU Connectivity is being used...
Findings demonstrate the need for comprehensive personalized tumor testing to deliver actionable insights and inform effective treatment plans San Francisco,...
Immunotherapy Company Will Present Findings at the JP Morgan Healthcare Conference in San Francisco on January 7th Second Round Crossover Funding...
Topics to include DNA and RNA profiling and next-generation sequencing of tumors San Antonio, TX – Dec 3, 2018 –...
Total Revenue in Q3 was $22.3 Million SaaS revenue of $15.9 million in Q3, up 5% from $15.2 million in...
NantHealth demonstrates new DeviceConX™ features including enterprise support for larger health systems and high fidelity waveform capture BRISBANE, AUSTRALIA and...
New DeviceConX Enhancements Showcased at the Healthcare Information and Management Systems Society (HIMSS) Interoperability Showcase™ Asia Pacific Conference and Exhibition...
–Slight Delay in Reporting Financial Results, Due to Effects of Hurricane Michael– CULVER CITY, Calif. – (November 6, 2018) —...
NantHealth’s Liquid GPS™ technology shows promise in the monitoring of key biomarkers in metastatic colorectal cancer MUNICH and CULVER CITY,...
Research shows that while on immunotherapy, plasma levels of PD-L1 expression can be used in order to monitor clinical responses....
Nikko Khazana and Mark Mozley will help drive growth of NantHealth’s portfolio, including GPS Cancer ® and Liquid GPS products....